We are live on ! Find out more
CLLS

Cellectis

51 hedge funds and large institutions have $54.7M invested in Cellectis in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more call options, than puts

Call options by funds: $277K | Put options by funds: $211K

6% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 16

6.42% less ownership

Funds ownership: 33.4%26.98% (-6.4%)

11% less funds holding

Funds holding: 5751 (-6)

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

56% less capital invested

Capital invested by funds: $124M → $54.7M (-$69M)

Holders
51
Holders Change
-6
Holders Change %
-10.53%
% of All Funds
0.8%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
9
Increased
15
Reduced
16
Closed
15
Calls
$277K
Puts
$211K
Net Calls
+$66K
Net Calls Change
-$23K

CLLS Hedge Fund Activity: Q1 2022 in Review

51 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q1 2022, worth a combined $54.7M — down 56% from $124M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of CLLS and 9 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 15 added.

The largest buyer was Long Focus Capital Management, adding an estimated $7.63M. The largest seller was ARK Investment Management, exiting entirely with an estimated $23.9M sold.

  • 51 institutional investors held Cellectis (CLLS) as of Q1 2022, down from 57 in Q4 2021.
  • Funds reported $54.7M of Cellectis stock for Q1 2022, down 56% quarter-over-quarter.
  • 9 funds opened new Cellectis positions in Q1 2022 and 15 closed out, a net change of -6 holders.
  • The largest Cellectis buyer in Q1 2022 was Long Focus Capital Management, an estimated $7.63M added.
  • The largest Cellectis seller in Q1 2022 was ARK Investment Management, an estimated $23.9M sold.

Based on aggregated 13F filings for Q1 2022.